Surprising activity of nilutamide in post-castration progressive prostate cancer
| Autor: | D. Lifsey, A. O. Sartor, A. C. Dwight |
|---|---|
| Rok vydání: | 2004 |
| Předmět: |
Cancer Research
medicine.medical_specialty LHRH Agonist business.industry Urology PSA PROGRESSION urologic and male genital diseases medicine.disease Surgery Prostate cancer chemistry.chemical_compound Castration Oncology Maintenance therapy chemistry Nilutamide medicine Orchiectomy business Clin oncol medicine.drug |
| Zdroj: | Journal of Clinical Oncology. 22:4762-4762 |
| ISSN: | 1527-7755 0732-183X |
| DOI: | 10.1200/jco.2004.22.90140.4762 |
| Popis: | 4762 Background: Increasingly patients with post-castration prostate cancer seek treatment for PSA only progression. Many of these patients are elderly, have considerable co-morbidities, are concerned about a rising PSA, and seek relatively non-toxic therapies. Methods: Twelve patients with progressive post-castration prostate cancer were treated with oral nilutamide at FDA approved doses (150 mg/day). LHRH agonist maintenance therapy was continued in non-surgically castrated patients. Monthly PSA monitoring was recommended. PSA progression was defined as a 25% increase from baseline or nadir with a minimum increase of 5 ng/ml as recommended by Bubley et al (J Clin Oncol 17:3461). Results: All patients had failed either orchiectomy (n=2) or LHRH agonist therapy (n=10) and had clear evidence of a rising PSA prior to starting nilutamide. Median age was 81 (range 62–87), median PSA was 12 ng/ml (range 2.7–92.1), and radiographically positive metastatic disease was present in 33% (4/12). Antiandrogens were pr... |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|